Compare TAOP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAOP | GTBP |
|---|---|---|
| Founded | 1993 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.6M |
| IPO Year | N/A | N/A |
| Metric | TAOP | GTBP |
|---|---|---|
| Price | $2.33 | $0.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 12-08-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,196,786.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $0.54 |
| 52 Week High | $24.75 | $4.10 |
| Indicator | TAOP | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 47.14 |
| Support Level | $2.03 | $0.58 |
| Resistance Level | $2.84 | $0.82 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 43.41 | 33.00 |
Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.